dr. F.Y.F.L. (Filip) de Vos

dr. F.Y.F.L. (Filip) de Vos

Assistant Professor - medical
dr. F.Y.F.L. (Filip) de Vos
  • Dept of Medical Oncology

Research Programs






1993 –   1996


1996 –   2000











Pre-MedicalSchool at Limburg   UniversityCenter,   Hasselt, Belgium 


MedicalSchool at University   of Antwerp, Antwerp, Belgium (MD)


PhD thesis: “Balance between desired and unwanted effects   of chemotherapeutic and anti-angiogenic drugs” at department of   Medical Oncology at the University    of Groningen, The   Netherlands


Degree: Medical Oncologist, University   of Rotterdam, The Netherlands


Additional training












12th Masterclass in Clinical   Oncology by the European School of

Oncology (ESO) and European   Society of Medical Oncology



Clinical   Trial Statistics for Non-Statisticians by the European

Organization   for Research and Treatment in Cancer (EORTC)


Basic   Course Legislation and Organization for Clinical Researchers




Professional  experience


2008 – 2010



2010 – 2011



2011 –   present




Fellow, Dept of Medical Oncology, ErasmusMedical   Center, Rotterdam,   The Netherlands


Staff member, Dept of Medical Oncology, Radboud   University Nijmegen Medical Centre, Nijmegen,   The Netherlands


Staff member, Dept of Medical Oncology, University of Utrecht,   Utrecht, the Netherlands


Since start of PhD thesis   extensive experience with clinical trials



Research Output (114)

Focused Ultrasound-Enhanced Liquid Biopsy:A Promising Diagnostic Tool for Brain Tumor Patients

Bakker Akke, Ixkes Anna E, Venugopal Hema, Ries Mario G, Lak Nathalie S M, de Vos Filip Y F L, van Vuurden Dannis G, Snijders Tom J 19 Apr 2024, In: Cancers. 16 , p. 1-15 15 p.

Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands:interlaboratory variation in the primary diagnostic and recurrent setting

van Opijnen Mark P, Broekman Marike L D, Cuppen Edwin, Dubbink Hendrikus J, Ter Elst Arja, van Eijk Ronald, Mühlebner Angelika, Jansen Casper, van der Geize Robert, Speel Ernst-Jan M, Groenen Patricia J T A, de Vos Filip Y F, Wesseling Pieter, de Leng Wendy W J, Maas Sybren L N 29 Jan 2024, In: Journal of Neuro-Oncology. 166 , p. 485-492 8 p.

The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?

van der Hiel Bernies, Aalbersberg Else A, van den Eertwegh Alfons J M, de Wit-van der Veen Linda J, Stokkel Marcel P M, Lopez-Yurda Marta, Boellaard Ronald, Kapiteijn Ellen W, Hospers Geke A P, Aarts Maureen J B, de Vos Filip Y F L, Boers-Sonderen Marye J, van der Veldt Astrid A M, de Groot Jan Willem B, Haanen John B A G 19 Dec 2023, In: Clinical Nuclear Medicine. 49 , p. 138-145 8 p.

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma:Results From the Drug Rediscovery Protocol

Spiekman Ilse A C, Geurts Birgit S, Zeverijn Laurien J, de Wit Gijs F, van der Noort Vincent, Roepman Paul, de Leng Wendy W J, Jansen Anne M L, Kusters Benno, Beerepoot Laurens V, de Vos Filip Y F L, de Groot Derk-Jan A, de Groot Jan Willem B, Hoeben Ann, Buter Jan, Gelderblom Hans A J, Voest Emile E, Verheul Henk M W 18 Dec 2023, In: The oncologist. 29 , p. 431-440 10 p.

Practice variation in re-resection for recurrent glioblastoma:A nationwide survey among Dutch neuro-oncology specialists

van Opijnen Mark P, de Vos Filip Y F, Nabuurs Rob J A, Snijders Tom J, Nandoe Tewarie Rishi D S, Taal Walter, Verhoeff Joost J C, van der Hoeven Jacobus J M, Broekman Marike L D 1 Aug 2023, In: Neuro-Oncology Practice. 10 , p. 360-369 10 p.

Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)

Reijneveld Jaap C, Machingura Abigirl, Coens Corneel, Taphoorn Martin J B, Taal Walter, Clement Paul M, Idbaih Ahmed, de Vos Filip Y F, Klein Martin, Wick Wolfgang, Mulholland Paul J, Lewis Joanne, Golfinopoulos Vassilis, Ghislain Irina, Bottomley Andrew, van den Bent Martin J, 19 Jun 2023, In: European Journal of Cancer. 190 , p. 1-15

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Pruis Melinda A, Krebs Matthew G, Plummer Ruth, De Vos Filip, Angevin Eric, Prenen Hans, Forster Martin D, Clack Glen, Van der Aa Annegret, Tjwa Marc, Jansen Ellen, Perera Timothy, Lolkema Martijn P 1 Jun 2023, In: Oncologist. 28 , p. e1248-e1258

Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020)

Padilla C S, Ho V K Y, Mooijenkind T W A N, Louwman M W J, de Vos F Y F L, Bekkenk M W, Minnaard W A, Loef C, van Zanten S E M Veldhuijzen 12 May 2023, In: Journal of Neuro-Oncology. 163 , p. 239-248 10 p.

Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced Cancer

van der Velden Naomi Cornelia Anna, Han Paul K J, van Laarhoven Hanneke W M, de Vos Filip Y F L, Hendriks Lizza E L, Burgers Sjaak A, Dingemans Anne-Marie C, van Haarst Jan Maarten W, Dits Joyce, Smets Ellen M A, Henselmans Inge 9 May 2023, In: Oncologist. 28 , p. e653-e668

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers:the phase 2 ROAR trial

Subbiah Vivek, Kreitman Robert J, Wainberg Zev A, Gazzah Anas, Lassen Ulrik, Stein Alexander, Wen Patrick Y, Dietrich Sascha, de Jonge Maja J A, Blay Jean-Yves, Italiano Antoine, Yonemori Kan, Cho Daniel C, de Vos Filip Y F L, Moreau Philippe, Fernandez Elena Elez, Schellens Jan H M, Zielinski Christoph C, Redhu Suman, Boran Aislyn, Passos Vanessa Q, Ilankumaran Palanichamy, Bang Yung-Jue 14 Apr 2023, In: Nature Medicine. 29 , p. 1103-1112 10 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not